Had dose increase of anti-TNF agent or DMARD in the last 6 months
Had change of anti-TNF agent or DMARD in the last 6 months
Treated currently with golimumab or certolizumab
Treated with greater than 10 mg of prednisone (or equivalent) daily in the last 6 months
Treated with greater than 5 mg of prednisone (or equivalent) daily in the last 3 months
Treated with intramuscular or intravenous corticosteroids in the last 6 months for RA activity
Treated with anakinra, abatacept, or tocilizumab in the last 6 months
Treated with rituximab in the last 12 months
Treated with an investigational RA drug in the last 6 months
Pregnant (or anticipate pregnancy during the study period) or lactating women
Absence of documentation in the medical record of clinical remission for the last 6 months
Unwilling to discontinue anti-TNF agent
Absence of documentation of negative tuberculin skin test, negative QuantiFERON-TB Gold test, or treatment for latent tuberculosis prior to starting treatment with the anti-TNF agent
Treatment of solid malignancy or non-melanoma skin cancer within the past 5 years, or any history of melanoma or hematologic or lymphoproliferative malignancy
Absence of documentation of age-appropriate cancer screening at the time of randomization
Absence of documentation of negative hepatitis B serologies, absence of completion of treatment for chronic hepatitis B, or absence of suppressive antiviral treatment
Unable to provide informed consent
Anticipate not being available or able to comply with the schedule of study visits

NCT01793519_exc_T1
Drug
anti-TNF agent
NCT01793519_exc_T2
Drug
DMARD
NCT01793519_exc_T3
Multiplier
dose increase
NCT01793519_exc_T4
Scope
anti-TNF agent or DMARD
NCT01793519_exc_T5
Drug
anti-TNF agent
NCT01793519_exc_T6
Drug
DMARD
NCT01793519_exc_T7
Procedure
change
NCT01793519_exc_T8
Scope
anti-TNF agent or DMARD
NCT01793519_exc_T9
Temporal
in the last 6 months
NCT01793519_exc_T10
Temporal
in the last 6 months
NCT01793519_exc_T11
Drug
golimumab
NCT01793519_exc_T12
Drug
certolizumab
NCT01793519_exc_T13
Multiplier
greater than 10 mg
NCT01793519_exc_T14
Drug
prednisone
NCT01793519_exc_T15
Multiplier
daily
NCT01793519_exc_T16
Temporal
in the last 6 months
NCT01793519_exc_T17
Multiplier
greater than 5 mg
NCT01793519_exc_T18
Drug
prednisone
NCT01793519_exc_T19
Multiplier
daily
NCT01793519_exc_T20
Temporal
in the last 3 months
NCT01793519_exc_T21
Qualifier
intramuscular
NCT01793519_exc_T22
Qualifier
intravenous
NCT01793519_exc_T23
Drug
corticosteroids
NCT01793519_exc_T24
Temporal
in the last 6 months
NCT01793519_exc_T25
Condition
RA
NCT01793519_exc_T26
Scope
intramuscular or intravenous
NCT01793519_exc_T27
Drug
anakinra
NCT01793519_exc_T28
Drug
abatacept
NCT01793519_exc_T29
Drug
tocilizumab
NCT01793519_exc_T30
Temporal
in the last 6 months
NCT01793519_exc_T31
Scope
anakinra, abatacept, or tocilizumab
NCT01793519_exc_T32
Drug
rituximab
NCT01793519_exc_T33
Temporal
in the last 12 months
NCT01793519_exc_T34
Qualifier
investigational
NCT01793519_exc_T35
Drug
RA drug
NCT01793519_exc_T36
Temporal
in the last 6 months
NCT01793519_exc_T37
Condition
Pregnant
NCT01793519_exc_T38
Condition
lactating
NCT01793519_exc_T39
Person
women
NCT01793519_exc_T40
Mood
e pregnanc e study period) or lact
NCT01793519_exc_T41
Condition
pregnancy
NCT01793519_exc_T42
Negation
Absence of
NCT01793519_exc_T43
Condition
clinical remission
NCT01793519_exc_T44
Temporal
for the last 6 months
NCT01793519_exc_T45
Mood
Unwilling
NCT01793519_exc_T46
Procedure
discontinue
NCT01793519_exc_T47
Drug
anti-TNF agent
NCT01793519_exc_T48
Negation
Absence of
NCT01793519_exc_T49
Value
negative
NCT01793519_exc_T50
Procedure
tuberculin skin test
NCT01793519_exc_T51
Value
negative
NCT01793519_exc_T52
Measurement
QuantiFERON-TB Gold test
NCT01793519_exc_T53
Qualifier
latent
NCT01793519_exc_T54
Condition
tuberculosis
NCT01793519_exc_T55
Procedure
treatment
NCT01793519_exc_T56
Temporal
prior to starting treatment with the anti-TNF agent
NCT01793519_exc_T57
Reference_point
starting treatment with the anti-TNF agent
NCT01793519_exc_T58
Procedure
treatment with the anti-TNF agent
NCT01793519_exc_T59
Drug
anti-TNF agent
NCT01793519_exc_T60
Condition
solid malignancy
NCT01793519_exc_T61
Condition
non-melanoma skin cancer
NCT01793519_exc_T62
Temporal
within the past 5 years
NCT01793519_exc_T63
Condition
melanoma
NCT01793519_exc_T64
Condition
hematologic
NCT01793519_exc_T65
Condition
lymphoproliferative malignancy
NCT01793519_exc_T67
Scope
solid malignancy or non-melanoma skin cancer
NCT01793519_exc_T66
Procedure
cancer screening
NCT01793519_exc_T68
Qualifier
age-appropriate
NCT01793519_exc_T69
Temporal
at the time of randomization
NCT01793519_exc_T70
Reference_point
the time of randomization
NCT01793519_exc_T71
Measurement
hepatitis B serologies
NCT01793519_exc_T72
Value
negative
NCT01793519_exc_T73
Negation
Absence of
NCT01793519_exc_T74
Procedure
treatment
NCT01793519_exc_T75
Condition
chronic hepatitis B
NCT01793519_exc_T76
Negation
absence of
NCT01793519_exc_T78
Procedure
suppressive antiviral treatment
NCT01793519_exc_T79
Negation
absence